Particle size characterization in nanosuspensions often focuses on ‘majority’ features of the size distribution. Yet, for various suspensions in (bio)pharmaceuticals or fine chemicals, small fractions ...

Protein-based therapeutics have transformed treatments for numerous diseases, yet their production remains highly complex and cost-intensive [1][2],[3][4]. Downstream processing (DSP), including ...

In biotherapeutic development, hitting roadblocks due to insufficient developability assessment is a common and costly setback. Traditional particle analysis methods demand more sample volume than is ...